A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of MEDI9447 (Oleclumab) in Japanese Patients with Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2018
At a glance
- Drugs Oleclumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 22 Nov 2018 Status changed from not yet recruiting to recruiting.
- 20 Nov 2018 Planned End Date changed from 19 Aug 2019 to 14 Aug 2019.
- 20 Nov 2018 Planned primary completion date changed from 19 Aug 2019 to 14 Aug 2019.